Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine controlled release - DURECT Corporation

Drug Profile

Bupivacaine controlled release - DURECT Corporation

Alternative Names: Optesia; POSIDUR; POSIMIR; SABER®-bupivacaine

Latest Information Update: 17 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DURECT Corporation
  • Developer DURECT Corporation; Takeda Pharmaceuticals International GmbH
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Postoperative pain

Most Recent Events

  • 09 May 2018 DURECT Corporation and Sandoz AG signed an amendment to the development and commercialisation agreement for bupivacaine controlled release in USA for postoperative pain
  • 01 Aug 2017 DURECT completes the phase III PERSIST trial in Postoperative pain in USA (NCT02574520)
  • 22 Jun 2017 DURECT completes enrolment in the phase III PERSIST trial in Postoperative pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top